<table><tr><td rowspan="2">510(k) Owner:</td><td rowspan="2">Contact: Hyman Katz, Ph.D. Phone: 973-852-0158 Fax:</td><td>Alfa Wassermann Diagnostic Technologies, LLC 4 Henderson Drive West Caldwell, NJ 07006</td></tr><tr><td>Hkatz@AlfaWassermannUS.com</td></tr><tr><td>Date Summary Prepared:</td><td colspan="2">973-852-0237 April 25, 2013</td></tr><tr><td>Device:</td><td colspan="2">Trade Name: ACE Carbon Dioxide (CO2-LC) Reagent Classification: Class 2. Enzymatic, Carbon-Dioxide</td></tr><tr><td rowspan="9"></td><td colspan="2">Common/Classification Name:</td></tr><tr><td colspan="2">(21 C: F.R. § 862.1160) Product Code KHS</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Trade Name: ACE Direct Bilirubin Reagent</td></tr><tr><td colspan="2">Classification: Class 2</td></tr><tr><td colspan="2">Common/Classification Name: Diazo Colorimetry, Bilirubin (21 C. F.R. § 862.1110)</td></tr><tr><td colspan="2">Product Code CIG</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Trade Name: ACE Total Bilirubin Reagent Classification: Class 2 Diazo Colorimetry, Bilirubin</td></tr><tr><td colspan="2">Common/Classification Name:</td></tr><tr><td colspan="2">(21 C. F.R. § 862.1110) Product Code CIG</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Trade Name: ACE Magnesium Reagent Classification: Class 1, reserved</td></tr><tr><td colspan="2">Common/Classification Name: Photometric Method, Magnesium (21 C. F.R. § 862.1495)</td></tr><tr><td></td><td></td></tr><tr><td>Predicate Devices:</td><td>Alfa Wassermann ACE Carbon Dioxide (CO2-LC) Reagent, ACE Direct Bilirubin Reagent, ACE Total Bilirubin Reagent, and ACE Magnesium Reagent (k931786)</td></tr><tr><td>Device Descriptions:</td><td>In the ACE Carbon Dioxide (CO2-LC) Reagent assay, serum carbon dioxide (in the form of bicarbonate) reacts with phosphoenolpyruvate in the presence of phosphoenolpyruvate carboxylase and magnesium to yield oxaloacetic acid and phosphate. In the presence of malate dehydrogenase, the reduced cofactor is oxidized by oxaloacetic acid. The reduced cofactor absorbs strongly at 408 nm whereas its oxidized form does not. The rate of decrease in absorbance, monitored bichromatically at 408 nm/692 nm, is proportional to the carbon dioxide content of the sample. In the ACE Direct Bilirubin Reagent assay, sodium nitrite added to sulfanilic acid forms diazotized sulfanilic acid. Bilirubin glucuronide in serum reacts with diazotized sulfanilic acid to form azobilirubin, which absorbs strongly at 554 nm. The increase in absorbance, measured bichromatically at 554 nm/692 nm, one minute after sample addi- tion, is directly proportional to the direct bilirubin concentration. In the ACE Total Bilirubin Reagent assay, sodium nitrite, when added to sulfanilic acid, forms diazotized sulfanilic acid. Bilirubin in serum reacts with diazotized sulfanilic acid to form azobilirubin, which absorbs strongly at 554 nm. The inclusion of dimethyl sulfoxide (DMSO) in the reagent as an accelerator causes both direct and indirect bilirubin to react rapidly. The increase in absorbance, measured bichromatically at 554</td></tr><tr><td colspan="2"></td></tr><tr><td>Intended Use:</td><td>Indications for Use:</td></tr><tr><td></td><td>The ACE Carbon Dioxide (CO2-LC) Reagent is intended for the quantitative determination of carbon dioxide concentration in serum and lithium heparin plasma using the ACE, ACE Alera® , and ACE Axcel Clinical Chemistry Systems. Bicarbonate/carbon dioxide measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE Direct Bilirubin Reagent is intended for the quantitative determination of direct bilirubin concentration in serum and lithium heparin plasma using the ACE,</td></tr><tr><td></td><td>ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders, including hepatitis and gall bladder block. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only The ACE Total Bilirubin Reagent is intended for the quantitative determination of total bilirubin concentration in serum and lithium heparin plasma using the ACE, ACE Alera and ACE Axcel Clinical Chemistry System. Measurements of the levels of</td></tr><tr><td></td><td>bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells is used in the diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders, including hepatitis and gall bladder block. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td></tr><tr><td></td><td>The ACE Magnesium Reagent is intended for the quantitative determination of magnesium in serum and lithium heparin plasma using the ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium). This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td></tr><tr><td>Technological Characteristics: Acid, DMSO and sodium Nitrite.</td><td>The ACE Carbon Dioxide (CO2-LC) Reagent consists of a single reagent bottle. The reagent contains Phosphoenolpyruvate, nicotinamide adenine dinucleotide, analog, reduced, phosphoenol pyruvate carboxylase and malate dehydrogenase. The ACE Direct Bilirubin Reagent is composed of two reagent bottles (Direct Bilirubin Reagent and Sodium Nitrite Reagent). The reagents contain Sulfanilic Acid, hydrochloric acid, and sodium nitrite. The ACE Total Bilirubin Reagent is composed of two reagent bottles (Total Bilirubin Reagent and Sodium Nitrite Reagent). The reagents contain sulfanilic acid, hydrochloric</td></tr></table>

<table><tr><td rowspan=14 colspan=2>earisonPredicate</td><td rowspan=1 colspan=3>:Comparison of similarities and differences with predicatedeviceACE Carbon Dioxide (CO2-LC) Reagent</td></tr><tr><td rowspan=1 colspan=1>CO2-LC</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK931786(ACE CO-LC)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The ACE Carbon Dioxide (CO2-LC) Reagent isintended for the quantitative determination of carbondioxide concentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel Clinical ChemistrySystems                                    .&#x27;</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>7 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>14 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>6μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>156 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>23 - 29 mEq/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>4 - 50 mEq/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Separated from cells, carbon dioxide is stable for 7days at 4-8°C and for 2 weeks at -20 C.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td></td><td></td><td></td></tr></table>

Device Comparison with Predicate   

<table><tr><td rowspan=1 colspan=3>ACE Direct Bilirubin Reagent</td></tr><tr><td rowspan=1 colspan=1>Direct Bilirubin</td><td rowspan=1 colspan=1>2aCandidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK931786(ACE DirectBilirubin</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Direct Bilirubin Reagent is intended for thequantitative determination of direct bilirubinconcentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>20 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>355 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>&lt;0.2 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>0.1 - 14.0 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Samples must be stored away from sunlight orfluorescent lights because bilirubin is subject tophotodegradation. Specimens may be stored at 4-8°Cfor 7 months or 6 months at -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Total Bilirubin Reagent

<table><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK931786(ACE TotalBilirubin)5.1</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Total Bilirubin Reagent is intended for thequantitative determination of total bilirubinconcentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Scrum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>20 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>380 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>0.3 - 1.2 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>0.2 - 40.0 mg/dL</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Samples must be stored away from sunlight orfluorescent lights because bilirubin is subject tophotodegradation. Serum samples must be analyzedwithin 7 days at 4-8 °C. Frozen samples are stable for6 months at -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Magnesium Reagent

Device Comparison with Predicate   

<table><tr><td rowspan=1 colspan=1>Magnesium</td><td rowspan=1 colspan=1>Candidate Device6</td><td rowspan=1 colspan=1>Predicate DeviceK931786  (ACE Magnesium)$a</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>ACE Magnesium Reagent is intended for thequantitative determination of magnesium.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 Day</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>488 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>1.6 - 2.6 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>0.4 - 6.1 mg/dL</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Serum magnesium is stable for 7 days at 4-8°C and1 year at -20 °C if the serum is separated from theerythrocytes.</td><td rowspan=1 colspan=1>Same</td></tr></table>

![](images/6e53d183dc0c80220230b4968429ecfb1f2b8579a8455dcb6171d581ca896eb3.jpg)

Performance Data:

In-House Precision - Serum vs. Plasma

In-House Precision: Serum vs. Plasma - ACE CO2-LC Reagent

Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems   

<table><tr><td rowspan=1 colspan=10>:-1.   $ i m:Precision (SD, %CV)-05-EF</td></tr><tr><td rowspan=1 colspan=1>CO2-LCmEq/L</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total&#x27;:.</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>0.27,1.1%</td><td rowspan=1 colspan=1>1.34,5.6%</td><td rowspan=1 colspan=1>24.6</td><td rowspan=1 colspan=1>0.61,2.5%</td><td rowspan=1 colspan=1>1.85,7.5%</td><td rowspan=1 colspan=1>23.9</td><td rowspan=1 colspan=1>0.48,2.0%</td><td rowspan=1 colspan=1>1.56.6.5%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>0.72,1.2%</td><td rowspan=1 colspan=1>1.22,3.6%</td><td rowspan=1 colspan=1>35.7</td><td rowspan=1 colspan=1>0.41,1.2%</td><td rowspan=1 colspan=1>1.17,3.3%</td><td rowspan=1 colspan=1>34.3</td><td rowspan=1 colspan=1>0.52,1.5%</td><td rowspan=1 colspan=1>1.26.3.7%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>0.57,2.8%</td><td rowspan=1 colspan=1>2.7,3.2%</td><td rowspan=1 colspan=1>47.0</td><td rowspan=1 colspan=1>0.55,1.2%</td><td rowspan=1 colspan=1>2.7,3.2%</td><td rowspan=1 colspan=1>45.4</td><td rowspan=1 colspan=1>0.25,0.6%</td><td rowspan=1 colspan=1>1.19,2.6%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>22.9</td><td rowspan=1 colspan=1>0.29,1.3%</td><td rowspan=1 colspan=1>0.86,3.8%</td><td rowspan=1 colspan=1>23.3</td><td rowspan=1 colspan=1>0.71,3.0%</td><td rowspan=1 colspan=1>1.43,6.1%</td><td rowspan=1 colspan=1>23.1</td><td rowspan=1 colspan=1>0.29,1.3%</td><td rowspan=1 colspan=1>0.86,3.8%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>0.41,1.2%</td><td rowspan=1 colspan=1>1.85,5.5%</td><td rowspan=1 colspan=1>34.8</td><td rowspan=1 colspan=1>0.34,1.0%</td><td rowspan=1 colspan=1>1.77,5.1%</td><td rowspan=1 colspan=1>33.8</td><td rowspan=1 colspan=1>0.24,0.7%</td><td rowspan=1 colspan=1>1.69,5.0%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>0.46,1.0%</td><td rowspan=1 colspan=1>1.14,2.5%</td><td rowspan=1 colspan=1>46.9</td><td rowspan=1 colspan=1>0.46,1.0%</td><td rowspan=1 colspan=1>1.10,2.4%</td><td rowspan=1 colspan=1>45.3</td><td rowspan=1 colspan=1>0.47,1.0%</td><td rowspan=1 colspan=1>1.05,2.3%</td></tr></table>

# In-House Precision: Serum vs. Plasma - ACE Direct Bilirubin Reagent

<table><tr><td rowspan=1 colspan=10>:Precision (SD, %CV)                    6           iiD</td></tr><tr><td rowspan=1 colspan=1>DirectBilirubinmg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>TotalRS</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean-z</td><td rowspan=1 colspan=1>aWithin-Run</td><td rowspan=1 colspan=1>Total}$</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.04,24.5%</td><td rowspan=1 colspan=1>0.05,30.0%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.03,16.0%</td><td rowspan=1 colspan=1>0.04,20.1%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.02,12.5%</td><td rowspan=1 colspan=1>0.02,14.0%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.04,0.9%</td><td rowspan=1 colspan=1>0.06,1.2%</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.06,1.4%</td><td rowspan=1 colspan=1>0.10,2.2%</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.08,1.6%</td><td rowspan=1 colspan=1>0.08,1.6%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.05,0.6%</td><td rowspan=1 colspan=1>0.09,1.1%</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>0.06,0.8%</td><td rowspan=1 colspan=1>0.09,1.1%</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>0.13,1.5%</td><td rowspan=1 colspan=1>0.14,1.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.03,26.6%</td><td rowspan=1 colspan=1>0.03,26.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.03,23.4%</td><td rowspan=1 colspan=1>0.05,35.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.02, 16.6</td><td rowspan=1 colspan=1>0.02,19.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.04,0.8%</td><td rowspan=1 colspan=1>0.05,1.1%</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.08,1.7%</td><td rowspan=1 colspan=1>0.13,2.8%</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.11,2.4%</td><td rowspan=1 colspan=1>0.11,2.4%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.09,1.1%</td><td rowspan=1 colspan=1>0.14,1.6%</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.06,0.7%</td><td rowspan=1 colspan=1>0.10,1.1%</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.16,1.9%</td><td rowspan=1 colspan=1>0.20,2.3%</td></tr></table>

Performance Data:

In-House Precision - Serum vs. Plasma

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)                                       $fra}$\frac}$vi</td></tr><tr><td rowspan=1 colspan=1>TotalBilirubinmg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1> Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.07,21.3%</td><td rowspan=1 colspan=1>0.07,21.3%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.04,11.0%</td><td rowspan=1 colspan=1>0.05,15.7%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.04,13.4%</td><td rowspan=1 colspan=1>0.04,13.9%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>0.13,1.0%</td><td rowspan=1 colspan=1>0.13,1.0%</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>0.14,1.1%</td><td rowspan=1 colspan=1>0.14,1.1%</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>0.13,1.0%</td><td rowspan=1 colspan=1>0.13,1.0%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0.18,0.7%</td><td rowspan=1 colspan=1>0.21,0.8%</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>0.12,0.5%</td><td rowspan=1 colspan=1>0.12,0.5%</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0.11,0.4%</td><td rowspan=1 colspan=1>0.17,0.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.04,20.3%</td><td rowspan=1 colspan=1>0.05,21.3%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.06,23.7%</td><td rowspan=1 colspan=1>0.07,29.4%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.04,20.6%</td><td rowspan=1 colspan=1>0.05,23.9%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.11,0.8%</td><td rowspan=1 colspan=1>0.12,0.9%</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>0.13,1.0%</td><td rowspan=1 colspan=1>0.14,1.1%</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.06,0.5%</td><td rowspan=1 colspan=1>0.07,0.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>26.2</td><td rowspan=1 colspan=1>0.15,· 0.6%</td><td rowspan=1 colspan=1>0.17,0.6%</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>0.12,0.5%</td><td rowspan=1 colspan=1>0.18,0.7%</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0.13,0.5%</td><td rowspan=1 colspan=1>0.14,0.5%</td></tr></table>

# In-House Precision: Serum vs. Plasma - ACE Magnesium Reagent

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)i:s</td></tr><tr><td rowspan=1 colspan=1>Magnesiummg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>WithinRun.</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.10,5.1%</td><td rowspan=1 colspan=1>0.12,5.9%</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.06,3.1%</td><td rowspan=1 colspan=1>0.09,4.3%</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.07,3.6%</td><td rowspan=1 colspan=1>0.08,4.3%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.09,2.5%</td><td rowspan=1 colspan=1>0.11,3.0%</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.06,1.7%</td><td rowspan=1 colspan=1>0.07,1.8%</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.09,2.6%</td><td rowspan=1 colspan=1>0.09,2.6%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.05,1.0%</td><td rowspan=1 colspan=1>0.10,1.7%</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.08,1.4%</td><td rowspan=1 colspan=1>0.09,1.6%</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.08,1.4%</td><td rowspan=1 colspan=1>0.09,1.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.08,4.7%</td><td rowspan=1 colspan=1>0.11,.6.2%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.06,3.5%</td><td rowspan=1 colspan=1>0.07,4.1%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.04,2.4%</td><td rowspan=1 colspan=1>0.11,6.8%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.09,2.7%</td><td rowspan=1 colspan=1>0.10,2.8%</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.09,2.4%</td><td rowspan=1 colspan=1>0.09,2.6%</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.09,2.8%</td><td rowspan=1 colspan=1>0.13.3.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.04,0.9%</td><td rowspan=1 colspan=1>0.10,1.9%</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.09,1.6%</td><td rowspan=1 colspan=1>0.10,1.8%</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.05,1.0%</td><td rowspan=1 colspan=1>0.09,1.8%</td></tr></table>

<table><tr><td>Performance Data: In-House Matrix</td><td rowspan="3">Comparison -</td></tr><tr><td>Serum vs. Plasma</td></tr><tr><td></td></tr></table>

<table><tr><td>Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE CO2-LC Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma       1</td></tr><tr><td rowspan=1 colspan=1>ACE53 pairs</td><td rowspan=1 colspan=1>4.9-47.9 mEq/L</td><td rowspan=1 colspan=1>Slope: 1.031Intercept: -1.03Correlation: 0.9922Std. Error Est: 1.13Confidence Interval Slope: 0.995 to 1.067Confidence Interval Intercept: -2.11 to 0.04</td></tr><tr><td rowspan=1 colspan=1>ACE Alera54 pairs</td><td rowspan=1 colspan=1>4.7-48.2 mEq/L</td><td rowspan=1 colspan=1>Slope: 1.000Intercept: -0.09Correlation: 0.9955Std. Error Est: 0.86Confidence Interval Slope: 0.974 to 1.027Confidence Interval Intercept: -0.81 to 0.64</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel51 pairs</td><td rowspan=1 colspan=1>5.5-47.9 mEq/L</td><td rowspan=1 colspan=1>Slope: 0.988Intercept: -0.35Correlation: 0.9889Std. Error Est: 1.12Confidence Interval Slope: 0.946 to 1.031Confidence Interval Intercept: -1.29 to 0.60</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE Direct Bilirubin Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE102 pairs</td><td rowspan=1 colspan=1>0.1-10.8 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.021Intercept: 0.00Correlation: 0.9982Std. Error Est: 0.10Confidence Interval Slope: 1.009 to 1.033Confidence Interval Intercept: -0.02 to 0.03</td></tr><tr><td rowspan=1 colspan=1>ACE Alera101 pairs</td><td rowspan=1 colspan=1>0.1-11.0 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.005Intercept: 0.01Correlation: 0.9978Std. Error Est: 0.11Confidence Interval Slope: 0.992 to 1.018Confidence Interval Intercept: -0.02 to 0.03</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel56 pairs</td><td rowspan=1 colspan=1>0.1-13.1 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.004Intercept: 0.00Correlation: 0.9983Std. Error Est: 0.16Confidence Interval Slope: 0.988 to 1.020Confidence Interval Intercept: -0.04 to 0.05</td></tr></table>

Performance

Data:

In-House   
Matrix   
Comparison - Serum vs.   
Plasma

In-House Matrix Comparison: Serum vs. Plasma - ACE Total Bilirubin Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma       $\frac { }$</td></tr><tr><td rowspan=1 colspan=1>ACE102 pairs</td><td rowspan=1 colspan=1>0.1-37.2 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.017Intercept: 0.01Correlation: 0.9996Std. Error Est: 0.15Confidence Interval Slope: 1.011 to 1.022Confidence Interval Intercept: -0.03 to 0.04</td></tr><tr><td rowspan=1 colspan=1>ACE Alera102 pairs</td><td rowspan=1 colspan=1>0.2-36.7 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.020Intercept: 0.00Correlation: 0.9993Std. Error Est: 0.20Confidence Interval Slope: 1.012 to 1.028Confidence Interval Intercept: -0.05 to 0).04</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel56 pairs</td><td rowspan=1 colspan=1>0.2-35.5 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.008Intercept: 0.00Correlation: 0.9995Std. Error Est: 0.22Confidence Interval Slope: 1.000 to 1.017Confidence Interval Intercept: -0.06 to 0.07</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma  ACE Magnesium Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>9   RangeSNE</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>. ACE101 pairs</td><td rowspan=1 colspan=1>1.2-5.8 mg/dL</td><td rowspan=1 colspan=1>Slope: 0.948Intercept: 0.08Correlation: 0.9703 Std. Error Est: 0.19Confidence Interval Slope: 0.902 to 0.994Confidence Interval Intercepl: -0.02 to 0.18</td></tr><tr><td rowspan=1 colspan=1>ACE Alera101 pairs</td><td rowspan=1 colspan=1>1.0-5.9 mg/dL</td><td rowspan=1 colspan=1>Slope: 0.986Intercept: 0.05Correlation: 0.9817Std. Error Est: 0.15Confidence Interval Slope: 0.948 to 1.024Confidence Interval Intercept: -0.06 to 0.10</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel55 pairs</td><td rowspan=1 colspan=1>1.2-5.8 mg/dL</td><td rowspan=1 colspan=1>Slope: 0.986Intercept: 0.025Correlation: 0.9892Std. Error Est: 0.125Confidence Interval Slope: 0.947 to 1.026Confidence Interval Intercept: -0.61 to 0.11 1</td></tr></table>

Performance

<table><tr><td>Data: Precision - POL</td></tr><tr><td></td></tr></table>

# POL - Precision studies at 3 POC sites for ACE Alera Clinical Chemistry Systems

(ACE system was also tested concurrently and comparable precision was obtained)

<table><tr><td colspan="3" rowspan="2">CO2_LC</td><td colspan="2" rowspan="1">ACE Result</td><td colspan="1" rowspan="3">Mean3:</td><td colspan="2" rowspan="1">ACE Alera Result</td></tr><tr><td colspan="2" rowspan="1">mEq/L SD, %CV</td><td colspan="2" rowspan="1">mEq/L SD, %CV</td></tr><tr><td colspan="1" rowspan="1">Gabb</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">Within-Run</td><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">$3a $Total3a$3</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">21.2</td><td colspan="1" rowspan="1">0.33 SD</td><td colspan="1" rowspan="1">0.63 SD</td><td colspan="1" rowspan="2">21.1</td><td colspan="1" rowspan="1">0.43 SD</td><td colspan="1" rowspan="1">0.81 SD</td></tr><tr><td colspan="1" rowspan="1">1.60%</td><td colspan="1" rowspan="1">3.00%</td><td colspan="1" rowspan="1">2.00%</td><td colspan="1" rowspan="1">3.90%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">20.3</td><td colspan="1" rowspan="1">0.68 SD</td><td colspan="1" rowspan="1">0.88 SD</td><td colspan="1" rowspan="2">22.3</td><td colspan="1" rowspan="1">0.28 SD</td><td colspan="1" rowspan="1">0.67 SD</td></tr><tr><td colspan="1" rowspan="1">3.30%</td><td colspan="1" rowspan="1">4.30%</td><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">3.00%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">23</td><td colspan="1" rowspan="1">0.55 SD</td><td colspan="1" rowspan="1">1.54 SD</td><td colspan="1" rowspan="2">22.4</td><td colspan="1" rowspan="1">0.59 SD</td><td colspan="1" rowspan="1">0.84 SD</td></tr><tr><td colspan="1" rowspan="1">2.40%</td><td colspan="1" rowspan="1">6.70%</td><td colspan="1" rowspan="1">2.60%</td><td colspan="1" rowspan="1">3.80%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">22.3</td><td colspan="1" rowspan="1">0.42 SD</td><td colspan="1" rowspan="1">1.10 SD</td><td colspan="1" rowspan="2">24.3</td><td colspan="1" rowspan="1">0.37 SD</td><td colspan="1" rowspan="1">1.53 SD</td></tr><tr><td colspan="1" rowspan="1">1.90%</td><td colspan="1" rowspan="1">4.90%</td><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">6.30%</td></tr><tr><td colspan="8" rowspan="1">S                                                      *3  :.    -.*</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">24.2</td><td colspan="1" rowspan="1">0.46 SD</td><td colspan="1" rowspan="1">0.66 SD</td><td colspan="1" rowspan="2">24.2</td><td colspan="1" rowspan="1">0.42 SD</td><td colspan="1" rowspan="1">0.77 SD</td></tr><tr><td colspan="1" rowspan="1">1.90%</td><td colspan="1" rowspan="1">2.70%</td><td colspan="1" rowspan="1">1.70%</td><td colspan="1" rowspan="1">3.20%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">24.9</td><td colspan="1" rowspan="1">0.77 SD</td><td colspan="1" rowspan="1">1.38 SD</td><td colspan="1" rowspan="2">25.6</td><td colspan="1" rowspan="1">0.32 SD</td><td colspan="1" rowspan="1">0.63 SD</td></tr><tr><td colspan="1" rowspan="1">3.10%</td><td colspan="1" rowspan="1">5.60%</td><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">2.40%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">26.2</td><td colspan="1" rowspan="1">0.43 SD</td><td colspan="1" rowspan="1">1.92 SD</td><td colspan="1" rowspan="2">26</td><td colspan="1" rowspan="1">0.24 SD</td><td colspan="1" rowspan="1">1.00 SD</td></tr><tr><td colspan="1" rowspan="1">1.70%</td><td colspan="1" rowspan="1">7.40%</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">3.90%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">25.9</td><td colspan="1" rowspan="1">0.34 SD</td><td colspan="1" rowspan="1">1.08 SD</td><td colspan="1" rowspan="2">27.8</td><td colspan="1" rowspan="1">0.29 SD</td><td colspan="1" rowspan="1">1.60 SD</td></tr><tr><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">4.20%</td><td colspan="1" rowspan="1">1.10%</td><td colspan="1" rowspan="1">5.80%</td></tr><tr><td colspan="8" rowspan="1">                                                                :3 *MEi</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">27.3</td><td colspan="1" rowspan="1">0.49 SD</td><td colspan="1" rowspan="1">0.65 SD</td><td colspan="1" rowspan="2">27</td><td colspan="1" rowspan="1">0.43 SD</td><td colspan="1" rowspan="1">0.83 SD</td></tr><tr><td colspan="1" rowspan="1">1.80%</td><td colspan="1" rowspan="1">2.40%</td><td colspan="1" rowspan="1">1.60%</td><td colspan="1" rowspan="1">3.10%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">30.4</td><td colspan="1" rowspan="1">0.73 SD</td><td colspan="1" rowspan="1">1.75 SD</td><td colspan="1" rowspan="2">28.4</td><td colspan="1" rowspan="1">0.39 SD</td><td colspan="1" rowspan="1">0.94 SD</td></tr><tr><td colspan="1" rowspan="1">2.40%</td><td colspan="1" rowspan="1">5.80%</td><td colspan="1" rowspan="1">1.40%</td><td colspan="1" rowspan="1">3.30%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">29.6</td><td colspan="1" rowspan="1">0.62 SD</td><td colspan="1" rowspan="1">1.88 SD</td><td colspan="1" rowspan="2">29.3</td><td colspan="1" rowspan="1">0.48 SD</td><td colspan="1" rowspan="1">0.94 SD</td></tr><tr><td colspan="1" rowspan="1">2.10%</td><td colspan="1" rowspan="1">6.40%</td><td colspan="1" rowspan="1">1.60%</td><td colspan="1" rowspan="1">3.20%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">29.5</td><td colspan="1" rowspan="1">0.26 SD</td><td colspan="1" rowspan="1">1.08 SD</td><td colspan="1" rowspan="2">30.7</td><td colspan="1" rowspan="1">0.29 SD</td><td colspan="1" rowspan="1">1.60 SD</td></tr><tr><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">3.60%</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">5.20%</td></tr><tr><td colspan="3" rowspan="2">DBILI</td><td colspan="2" rowspan="1">ACE Result</td><td colspan="2" rowspan="2"></td><td colspan="2" rowspan="1">ACE Alera Result</td></tr><tr><td colspan="2" rowspan="1">mg/dL SD, %CV</td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">mg/dL SD, %CV</td></tr><tr><td colspan="1" rowspan="1">Lab</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">Total</td><td colspan="2" rowspan="1">Mean</td><td colspan="1" rowspan="1">Within-Run; z</td><td colspan="1" rowspan="1">Totalx</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">1.0</td><td colspan="1" rowspan="1">0.03 SD</td><td colspan="1" rowspan="1">0.03 SD</td><td colspan="2" rowspan="2">1.0</td><td colspan="1" rowspan="1">0.05 SD</td><td colspan="1" rowspan="1">0.05 SD</td></tr><tr><td colspan="1" rowspan="1">2.90%</td><td colspan="1" rowspan="1">2.90%</td><td colspan="1" rowspan="1">5.10%</td><td colspan="1" rowspan="1">5.40%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.04 SD</td><td colspan="1" rowspan="1">0.05 SD</td><td colspan="2" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.04 SD</td><td colspan="1" rowspan="1">0.05 SD</td></tr><tr><td colspan="1" rowspan="1">4.20%</td><td colspan="1" rowspan="1">4.90%</td><td colspan="1" rowspan="1">4.80%</td><td colspan="1" rowspan="1">5.40%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.03 SD</td><td colspan="1" rowspan="1">0.05 SD</td><td colspan="2" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.02 SD</td><td colspan="1" rowspan="1">0.02 SD</td></tr><tr><td colspan="1" rowspan="1">3.30%</td><td colspan="1" rowspan="1">5:20%</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">2.50%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">1</td><td colspan="1" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.03 SD</td><td colspan="1" rowspan="1">0.03 SD</td><td colspan="2" rowspan="2">0.9</td><td colspan="1" rowspan="1">0.00 SD</td><td colspan="1" rowspan="1">0.00 SD</td></tr><tr><td colspan="1" rowspan="1">3.50%</td><td colspan="1" rowspan="1">3.50%</td><td colspan="1" rowspan="1">0.00%</td><td colspan="1" rowspan="1">0.00%</td></tr><tr><td colspan="9" rowspan="1">*5,</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">5.0</td><td colspan="1" rowspan="1">0.05 SD</td><td colspan="1" rowspan="1">0.07 SD</td><td colspan="2" rowspan="2">4.9</td><td colspan="1" rowspan="1">0.07 SD</td><td colspan="1" rowspan="1">0.09 SD</td></tr><tr><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">1.90%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">4.9</td><td colspan="1" rowspan="1">0.09 SD</td><td colspan="1" rowspan="1">0.10 SD</td><td colspan="2" rowspan="2">4.8</td><td colspan="1" rowspan="1">0.05 SD</td><td colspan="1" rowspan="1">0.05 SD</td></tr><tr><td colspan="1" rowspan="1">1.80%</td><td colspan="1" rowspan="1">2.10%</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">1.00%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">4.8</td><td colspan="1" rowspan="1">0.07 SD</td><td colspan="1" rowspan="1">0.12 SD</td><td colspan="2" rowspan="2">4.8</td><td colspan="1" rowspan="1">0.07 SD</td><td colspan="1" rowspan="1">0.08 SD</td></tr><tr><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">1.70%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">2</td><td colspan="1" rowspan="2">4.7</td><td colspan="1" rowspan="1">0.10 SD</td><td colspan="1" rowspan="1">0.11 SD</td><td colspan="2" rowspan="2">4.9</td><td colspan="1" rowspan="1">0.10 SD</td><td colspan="1" rowspan="1">0.10 SD</td></tr><tr><td colspan="1" rowspan="1">2.10%</td><td colspan="1" rowspan="1">2.40%</td><td colspan="1" rowspan="1">2.00%</td><td colspan="1" rowspan="1">2.00%</td></tr><tr><td colspan="9" rowspan="1">√               ..*.</td></tr><tr><td colspan="1" rowspan="2">In-House</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">8.0</td><td colspan="1" rowspan="1">0.18 SD</td><td colspan="1" rowspan="1">0.18 SD</td><td colspan="2" rowspan="2">7.8</td><td colspan="1" rowspan="1">0.20 SD</td><td colspan="1" rowspan="1">0.20 SD</td></tr><tr><td colspan="1" rowspan="1">2.30%</td><td colspan="1" rowspan="1">2.30%</td><td colspan="1" rowspan="1">2.60%</td><td colspan="1" rowspan="1">2.60%</td></tr><tr><td colspan="1" rowspan="2">POL 1</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">7.9</td><td colspan="1" rowspan="1">0.16 SD</td><td colspan="1" rowspan="1">0.17 SD</td><td colspan="2" rowspan="2">7.9</td><td colspan="1" rowspan="1">0.06 SD</td><td colspan="1" rowspan="1">0.07 SD</td></tr><tr><td colspan="1" rowspan="1">2.00%</td><td colspan="1" rowspan="1">2.20%</td><td colspan="1" rowspan="1">0.80%</td><td colspan="1" rowspan="1">0.90%</td></tr><tr><td colspan="1" rowspan="2">POL 2</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">7.7</td><td colspan="1" rowspan="1">0.10 SD</td><td colspan="1" rowspan="1">0.16 SD</td><td colspan="2" rowspan="2">7.8</td><td colspan="1" rowspan="1">0.04 SD</td><td colspan="1" rowspan="1">0.10 SD</td></tr><tr><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">2.00%</td><td colspan="1" rowspan="1">0.60%</td><td colspan="1" rowspan="1">1.30%</td></tr><tr><td colspan="1" rowspan="2">POL 3</td><td colspan="1" rowspan="2">3</td><td colspan="1" rowspan="2">7.7,</td><td colspan="1" rowspan="1">0.09 SD</td><td colspan="1" rowspan="1">0.12 SD</td><td colspan="2" rowspan="2">8.0</td><td colspan="1" rowspan="1">0.08 SD</td><td colspan="1" rowspan="1">0.08 SD</td></tr><tr><td colspan="1" rowspan="1">1.20%</td><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">1.10%</td></tr></table>

<table><tr><td>Performance Data at POL: Precision- POL</td></tr><tr><td></td><td></td></tr><tr><td>Performance Data at POL:</td><td rowspan="3"></td></tr><tr><td>Precision - POL</td></tr><tr><td></td></tr></table>

<table><tr><td rowspan=2 colspan=3>TBILI</td><td rowspan=1 colspan=2>ACE Result.</td><td rowspan=3 colspan=1>Mean-:SENT2.</td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dLSD, %CV</td><td rowspan=1 colspan=2>mg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-z3.Run; :-</td><td rowspan=1 colspan=1>Total;</td></tr><tr><td rowspan=2 colspan=1>. In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.2</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=2 colspan=1>1.2</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.05 SD</td></tr><tr><td rowspan=1 colspan=1>3.40%</td><td rowspan=1 colspan=1>3.70%</td><td rowspan=1 colspan=1>4.20%</td><td rowspan=1 colspan=1>4.50%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.2</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=2 colspan=1>1.2</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.04 SD</td></tr><tr><td rowspan=1 colspan=1>5.50%</td><td rowspan=1 colspan=1>5.80%</td><td rowspan=1 colspan=1>3.20%</td><td rowspan=1 colspan=1>3.70%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.1</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=2 colspan=1>1.2</td><td rowspan=1 colspan=1>0.06 SD</td><td rowspan=1 colspan=1>0.06 SD</td></tr><tr><td rowspan=1 colspan=1>4.00%</td><td rowspan=1 colspan=1>6.40%</td><td rowspan=1 colspan=1>4.90%</td><td rowspan=1 colspan=1>5.00%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.1</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=2 colspan=1>1.1</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.06 SD</td></tr><tr><td rowspan=1 colspan=1>3.40%</td><td rowspan=1 colspan=1>4.40%</td><td rowspan=1 colspan=1>4.80%</td><td rowspan=1 colspan=1>5.20%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=6>33                                             -MS           te </td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>11.5</td><td rowspan=1 colspan=1>0.20 SD</td><td rowspan=1 colspan=1>0.20 SD</td><td rowspan=2 colspan=1>11.3</td><td rowspan=1 colspan=1>0.23 SD</td><td rowspan=1 colspan=1>0.24 SD</td></tr><tr><td rowspan=1 colspan=1>1.70%</td><td rowspan=1 colspan=1>1.80%</td><td rowspan=1 colspan=1>2.00%</td><td rowspan=1 colspan=1>2.10%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>11.2</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.42 SD</td><td rowspan=2 colspan=1>11.4</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.09 SD</td></tr><tr><td rowspan=1 colspan=1>0.50%</td><td rowspan=1 colspan=1>3.70%</td><td rowspan=1 colspan=1>0.70%</td><td rowspan=1 colspan=1>0.80%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>11.3</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.15 SD</td><td rowspan=2 colspan=1>11.3</td><td rowspan=1 colspan=1>0.17 SD</td><td rowspan=1 colspan=1>0.17 SD</td></tr><tr><td rowspan=1 colspan=1>0.50%</td><td rowspan=1 colspan=1>1.30%</td><td rowspan=1 colspan=1>1.50%</td><td rowspan=1 colspan=1>1.50%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>10.9</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>11.2</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.09 SD</td></tr><tr><td rowspan=1 colspan=1>0.80%</td><td rowspan=1 colspan=1>1.00%</td><td rowspan=1 colspan=1>0.80%</td><td rowspan=1 colspan=1>0.80%</td></tr><tr><td rowspan=1 colspan=8>                                          2A                      SAS9A       S.</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>20.9</td><td rowspan=1 colspan=1>0.24 SD</td><td rowspan=1 colspan=1>0.27 SD</td><td rowspan=2 colspan=1>20.6</td><td rowspan=1 colspan=1>0.27 SD</td><td rowspan=1 colspan=1>0.35 SD</td></tr><tr><td rowspan=1 colspan=1>1.10%</td><td rowspan=1 colspan=1>1.30%</td><td rowspan=1 colspan=1>1.30%</td><td rowspan=1 colspan=1>1.70%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>20.0</td><td rowspan=1 colspan=1>0.24 SD</td><td rowspan=1 colspan=1>0.24 SD</td><td rowspan=2 colspan=1>20.7</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.12 SD</td></tr><tr><td rowspan=1 colspan=1>1.20%</td><td rowspan=1 colspan=1>1.20%</td><td rowspan=1 colspan=1>0.50%</td><td rowspan=1 colspan=1>0.60%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>20.3</td><td rowspan=1 colspan=1>0.21 SD</td><td rowspan=1 colspan=1>0.42 SD</td><td rowspan=2 colspan=1>20.5</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.15 SD</td></tr><tr><td rowspan=1 colspan=1>1.00%</td><td rowspan=1 colspan=1>2.10%</td><td rowspan=1 colspan=1>0.50%</td><td rowspan=1 colspan=1>0.70%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>19.9</td><td rowspan=1 colspan=1>0.24 SD</td><td rowspan=1 colspan=1>0.26 SD</td><td rowspan=2 colspan=1>20.3</td><td rowspan=1 colspan=1>0.28 SD</td><td rowspan=1 colspan=1>0.28 SD</td></tr><tr><td rowspan=1 colspan=1>1.20%</td><td rowspan=1 colspan=1>1.30%</td><td rowspan=1 colspan=1>1.40%</td><td rowspan=1 colspan=1>1.40%</td></tr></table>

<table><tr><td rowspan=2 colspan=3>MG</td><td rowspan=1 colspan=2>ACE Result</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dL SD, %CV</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>mg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total:³</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.07 SD</td></tr><tr><td rowspan=1 colspan=1>3.30%</td><td rowspan=1 colspan=1>5.70%</td><td rowspan=1 colspan=1>3.00%</td><td rowspan=1 colspan=1>4.50%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.10 SD</td></tr><tr><td rowspan=1 colspan=1>3.30%</td><td rowspan=1 colspan=1>6.30%</td><td rowspan=1 colspan=1>4.20%</td><td rowspan=1 colspan=1>5.90%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.8</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=2 colspan=1>1.5</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.13 SD</td></tr><tr><td rowspan=1 colspan=1>4.60%</td><td rowspan=1 colspan=1>5.00%</td><td rowspan=1 colspan=1>6.00%</td><td rowspan=1 colspan=1>8.40%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.06 SD</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.11 SD</td></tr><tr><td rowspan=1 colspan=1>3.00%</td><td rowspan=1 colspan=1>3.50%</td><td rowspan=1 colspan=1>3.90%</td><td rowspan=1 colspan=1>6.50%</td></tr><tr><td rowspan=1 colspan=8>..                                                                              ::-</td></tr></table>

<table><tr><td rowspan=17 colspan=1>PerformanceData at POL:Precision-POL</td><td rowspan=17 colspan=1></td><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>3.7</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.12 SD</td><td rowspan=2 colspan=1>3.6</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.09 SD</td></tr><tr><td rowspan=1 colspan=1>2.50%</td><td rowspan=1 colspan=1>3.30%</td><td rowspan=1 colspan=1>2.00%</td><td rowspan=1 colspan=1>2.50%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>3.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>3.8</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.13 SD</td></tr><tr><td rowspan=1 colspan=1>1.30%</td><td rowspan=1 colspan=1>3.00%</td><td rowspan=1 colspan=1>2.80%</td><td rowspan=1 colspan=1>3.60%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>3.7</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=2 colspan=1>3.5</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.18 SD</td></tr><tr><td rowspan=1 colspan=1>1.90%</td><td rowspan=1 colspan=1>3.50%</td><td rowspan=1 colspan=1>2.90%</td><td rowspan=1 colspan=1>5.20%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>3.6</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=2 colspan=1>3.7</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.13 SD</td></tr><tr><td rowspan=1 colspan=1>2.50%</td><td rowspan=1 colspan=1>2.80%</td><td rowspan=1 colspan=1>2.10%</td><td rowspan=1 colspan=1>3.60%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=6></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>5.6</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.14 SD</td><td rowspan=2 colspan=1>5.5</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.10 SD</td></tr><tr><td rowspan=1 colspan=1>1.80%</td><td rowspan=1 colspan=1>2.60%</td><td rowspan=1 colspan=1>1.00%</td><td rowspan=1 colspan=1>1.80%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>5.7</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>5.8</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.12 SD</td></tr><tr><td rowspan=1 colspan=1>1.60%</td><td rowspan=1 colspan=1>1.90%</td><td rowspan=1 colspan=1>1.40%</td><td rowspan=1 colspan=1>2.10%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>5.6</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.17 SD</td><td rowspan=2 colspan=1>5.4</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.26 SD</td></tr><tr><td rowspan=1 colspan=1>1.60%</td><td rowspan=1 colspan=1>3.10%</td><td rowspan=1 colspan=1>1.90%</td><td rowspan=1 colspan=1>4.80%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>5.5</td><td rowspan=1 colspan=1>0.06 SD</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=2 colspan=1>5.5</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.09 SD</td></tr><tr><td rowspan=1 colspan=1>1.10%</td><td rowspan=1 colspan=1>1.40%</td><td rowspan=1 colspan=1>0.90%</td><td rowspan=1 colspan=1>1.60%</td></tr></table>

Performance Data:   
Method   
Comparison - POL on ACE

<table><tr><td></td><td>Statistic</td><td>In-House ACE (x) vS. POL 1 ACE (y)</td><td>In-House ACE (x) vS. POL 2 ACE (y)</td><td>In-House ACE vS. POL 3 ACE (y)</td></tr><tr><td rowspan="3">C02-LC</td><td>n Range</td><td>46 3.6 to 42.5</td><td>45</td><td>45</td></tr><tr><td></td><td></td><td>3.6 to 46.2</td><td>3.6 to 46.2</td></tr><tr><td>Regression Correlation</td><td>y = 0.963x - 0.71 0.9710</td><td>y = 0.976x + 1.29 0.9530</td><td>y = 0.984x + 0.42</td></tr><tr><td rowspan="3"></td><td>Std. Error Est.</td><td>1.38</td><td>2.10</td><td>0.9908 0.94</td></tr><tr><td>CI Slope</td><td>0.893 to 1.034</td><td>0.884 to 1.069</td><td>0.943 to 1.025</td></tr><tr><td>Cl Intercept</td><td>-2.34 to 0.92</td><td>-0.91 to 3.49</td><td>-0.56 to 1.40</td></tr><tr><td rowspan="6">Direct Bilirubin</td><td>n</td><td>49</td><td>49</td><td>49</td></tr><tr><td>Range</td><td>0.1 to 12.4</td><td>0.1 to 12.4</td><td>0.1 to 12.4</td></tr><tr><td>Regression</td><td>y = 1.022x + 0.04</td><td>y = 1.003x + 0.11</td><td>y = 1.012x + 0.06</td></tr><tr><td>Correlation</td><td>0.9986</td><td>0.9985</td><td>0.9984</td></tr><tr><td>Std. Error Est.</td><td>0.14</td><td>0.14</td><td>0.14</td></tr><tr><td>CI Slope CI Intercept</td><td>1.006 to 1.038 0.00 to 0.08</td><td>0.987 to 1.019 0.07 to 0.15</td><td>0.995 to 1.029 0.02 to 0.11</td></tr><tr><td rowspan="6">Total Bilirubin</td><td>n Range</td><td>48 0.2 to 39.3</td><td>50 0.2 to 39.3</td><td>49</td></tr><tr><td></td><td></td><td></td><td>0.2 to 39.3</td></tr><tr><td>Regression</td><td>y = 0.979x + 0.00</td><td>y = 1.000x + 0.04</td><td>y = 1.000x + 0.01</td></tr><tr><td>Correlation</td><td>0.9995</td><td>0.9998</td><td>0.9998</td></tr><tr><td>Std. Error Est.</td><td>0.27</td><td>0.18</td><td>0.17</td></tr><tr><td>CI Slope CI Intercept</td><td>0.970 to 0.989 -0.08 to 0.08</td><td>0.994 to 1.006 -0.01 to 0.09</td><td>0.994 to 1.006</td></tr><tr><td rowspan="6"></td><td>n</td><td>51</td><td>52</td><td>-0.05 to 0.06 51</td></tr><tr><td>Range</td><td>0.6 to 6.1</td><td>0.6 to 6.1</td><td></td></tr><tr><td></td><td></td><td></td><td>0.6 1o 6.1</td></tr><tr><td>Regression</td><td>y = 0.970x + 0.12</td><td>y = 0.975x + 0.16</td><td>y = 1.026x - ().0)4</td></tr><tr><td>Correlation</td><td>0.9902</td><td>0.9927</td><td>0.9925</td></tr><tr><td>Std. Error Est.</td><td>0.13</td><td>0.11</td><td>0.12</td></tr><tr><td>CI Slope CI Intercept</td><td>0.931 to 1.009 0.03 to 0.21</td><td>0.941 to 1.008 0.08 to 0.23</td><td>0.989 to 1.062 -0.13 to 0.04</td></tr></table>

Performance Data at POL:

Method   
Comparison - POL on ACE Alera

POL  Method Comparison (performed at POC sites) for ACE Alera Clinical Chemistry System against the predicate device tested in-house   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House ACE (x)VS.POL 1 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 2 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vs.POL 3 Alera (y)</td></tr><tr><td rowspan=1 colspan=1>C02-LC</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>452.0 to 46.0y = 0.984x + 0.150.99030.950.941 to 1.026-0.81 to 1.12</td><td rowspan=1 colspan=1>452.0 to 46.0y = 0.972x + 0.570.97671.450.908 to 1.037-0.90 to 2.05</td><td rowspan=1 colspan=1>462.0 to 46.0y = 0.987x + 0.100.97901.380.926 to 1.049-1.30 to 1.50</td></tr><tr><td rowspan=1 colspan=1>DirectBilirubin</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>510.1 to 12.4y = 0.995x + 0.090.99910.100.983 to 1.0070.05 to 0.12</td><td rowspan=1 colspan=1>510.1 to 12.4y = 0.969x + 0.110.99840.140.953 to 0.9850.07 to 0.15</td><td rowspan=1 colspan=1>510.1 to 12.4y = 0.991 x + 0.100.99900.110.979 to 1.0040.06 to 0.13</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>500.2 to 39.4y = 1.020x + 0.020.99980.181.013 to 1.026-0.03 to 0.08</td><td rowspan=1 colspan=1>500.2 to 39.4y = 0.957x + 0.070.99910.340.945 to 0.968-0.03 to 0.17</td><td rowspan=1 colspan=1>500.2 to 39.4y = 0.981x + 0.010.99980.160.976 to 0.987-0.04 to 0.06</td></tr><tr><td rowspan=1 colspan=1>Magnesium</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>500.7 to 5.9y = 1.010x + 0.000.98700.120.963 to 1.057-0.10 to 0.10</td><td rowspan=1 colspan=1>500.7 to 5.9y = 1.004x - 0.110.98860.110.960 to 1.048-0.20 to -0.02</td><td rowspan=1 colspan=1>500.7 to 5.9y = 0.990x - 0.070.99300.090.956 to 1.024-0.14 to 0.00</td></tr></table>

Performance Data:

ACE Alera

# Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE Alera Clinical Chemistry Systems

Detection Limits - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>ACE Alera</td><td rowspan=1 colspan=1>CO2(mEq/L)</td><td rowspan=1 colspan=1>DBILI(mg/dL)</td><td rowspan=1 colspan=1>TBILI(mg/dL)</td><td rowspan=1 colspan=1>MG(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.26</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.08.</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.37</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>3.03</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.37</td></tr></table>

# Linearity - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>ACEReagents</td><td rowspan=1 colspan=1>Low leveltested</td><td rowspan=1 colspan=1>Upper leveltested</td><td rowspan=1 colspan=1>Linear to:</td><td rowspan=1 colspan=1>5Linear RegressionEquation  i. x2.   n</td></tr><tr><td rowspan=1 colspan=1>C02(mEq/L)</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>53.0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>y=1.006x + 0.01</td></tr><tr><td rowspan=1 colspan=1>DBILI(mg/dL)</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>14.0</td><td rowspan=1 colspan=1>y=1.015x + 0.16</td></tr><tr><td rowspan=1 colspan=1>TBILI(mg/dL)</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>41.6</td><td rowspan=1 colspan=1>40.0</td><td rowspan=1 colspan=1>y=1.004x + 0.03</td></tr><tr><td rowspan=1 colspan=1>MG(mg/dL)</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>y=0.959x + 0.27</td></tr></table>

Performance Data:

ACE Alera

<table><tr><td rowspan=1 colspan=1>ACEAlera</td><td rowspan=1 colspan=1>Icterus</td><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>Lipemia(Intralipid)/Triglycerides</td><td rowspan=1 colspan=1>Ascorbic AcidE }</td></tr><tr><td rowspan=1 colspan=1>C02</td><td rowspan=1 colspan=1>No significantinterferenceat or below58.8 mg/dL</td><td rowspan=1 colspan=1>No significantinterferenceat or below250 mg/dL</td><td rowspan=1 colspan=1>No significantinterferenceat or below2388 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterferenceat or below6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>DBili</td><td rowspan=1 colspan=1>Not Applicable</td><td rowspan=1 colspan=1>No significantinterferenceat or below62.5 mg/dL</td><td rowspan=1 colspan=1>No significantinterferenceat or below782 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterferenceat or below6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>TBili</td><td rowspan=1 colspan=1>Not Applicable</td><td rowspan=1 colspan=1>No significantinterferenceat or below62.5 mg/dL</td><td rowspan=1 colspan=1>No significantinterferenceat or below951 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterferenceat or below6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>MG</td><td rowspan=1 colspan=1>No significantinterferenceat or below50 mg/dL</td><td rowspan=1 colspan=1>No significantinterferenceat or below500 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow620 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterferenceat or below6 mg/dL</td></tr></table>

Performance Data: ACE Alera

<table><tr><td rowspan=2 colspan=2>on ACE Alera</td><td rowspan=1 colspan=3>Precision (SD, %CV) :        , 22 p vt,</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>C02. mEq/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.55, 4.3%</td><td rowspan=1 colspan=1>1.20, 9.4%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>15.2</td><td rowspan=1 colspan=1>0.48, 3.2%</td><td rowspan=1 colspan=1>1.49, 9.8%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>21.7</td><td rowspan=1 colspan=1>0.82, 3.8%</td><td rowspan=1 colspan=1>2.58, 11.9%</td></tr><tr><td rowspan=3 colspan=1>DBILImg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.02, 5.3%</td><td rowspan=1 colspan=1>0.02, 6.5%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.04, 2.6%</td><td rowspan=1 colspan=1>0.11, 6.6%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.08, 2.7%</td><td rowspan=1 colspan=1>0.18, 5.6%</td></tr><tr><td rowspan=3 colspan=1>TBILImg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.03, 5.7%</td><td rowspan=1 colspan=1>0.04, 8.5%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.04, 1.2%</td><td rowspan=1 colspan=1>0.13, 4.1%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.08, 1.1%</td><td rowspan=1 colspan=1>0.28, 3.7%</td></tr><tr><td rowspan=3 colspan=1>MGmg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.07, 4.3%</td><td rowspan=1 colspan=1>0.08, 5.1%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.07, 2.6%</td><td rowspan=1 colspan=1>0.09, 3.7%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.10, 2.7%</td><td rowspan=1 colspan=1>0.12, 3.3%</td></tr></table>

In-House ACE (x) vs. In-House ACE Alera (y)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>CO2(mEq/L)</td><td rowspan=1 colspan=1>DBILI(mg/dL)</td><td rowspan=1 colspan=1>TBILI(mg/dL)</td><td rowspan=1 colspan=1>MG(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>3.6 to 46.2</td><td rowspan=1 colspan=1>0.1 to 12.4</td><td rowspan=1 colspan=1>0.2 to 39.3</td><td rowspan=1 colspan=1>0.6 to 6.1</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.981</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>1.001</td><td rowspan=1 colspan=1>0.960</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.6</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.12</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9974</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.9906</td></tr><tr><td rowspan=1 colspan=1>Std. Error</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.10</td></tr><tr><td rowspan=1 colspan=1>CI Slope</td><td rowspan=1 colspan=1>0.918 to 1.045</td><td rowspan=1 colspan=1>0.993 to 1.003</td><td rowspan=1 colspan=1>0.999 to 1.003</td><td rowspan=1 colspan=1>0.922 to 0.998</td></tr><tr><td rowspan=1 colspan=1>CI Intercept</td><td rowspan=1 colspan=1>-2.12 to 0.91</td><td rowspan=1 colspan=1>-0.01 to 0.01</td><td rowspan=1 colspan=1>-0.02 to 0.02</td><td rowspan=1 colspan=1>0.04 to 0.21</td></tr></table>

<table><tr><td>Performance Data: ACE Alera Conclusions:</td></tr><tr><td></td></tr></table>

<table><tr><td>Conclusions:</td><td>Based on the foregoing data, the device is safe and effective for use in clinical laboratories and physician office laboratories. These data indicate substantial equivalence</td></tr><tr><td></td><td>for lithium heparin plasma sample collection tubes to the predicate device&#x27;s use of serum sample collection tubes.</td></tr></table>

May 2, 2013

Alfa Wasserman Diagnostic Technologies, LLC C/O Hyman Katz, Ph.D.   
4 Henderson Drive   
WEST CALDWELL NJ 07006

Re: K123953 Trade/Device Name: ACE Carbon Dioxide (CO2-LC) Reagent ACE Direct Bilirubin Reagent ACE Total Bilirubin Reagent ACE Magnesium Reagent Regulation Number: 21 CFR 862.1160 Regulation Name: Bicarbonate/carbon dioxide test system Regulatory Class: II Product Code: KHS, CIG, JGJ Dated: March 22, 2013 Received: March 25, 2013

Dear Dr. Katz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 1, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2—Dr. Katz

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucmI 15809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address hitp://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours, Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): k123953

# Device Name:

ACE Carbon Dioxide ( $\mathbf { C O } _ { 2 }$ LC) Reagent

Indications for Use: The ACE Carbon Dioxide (CO2-LC) Reagent is intended for the quantitative determination of carbon dioxide concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Bicarbonate/carbon dioxide measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

# Device Name:

ACE Direct Bilirubin Reagent

Indications for Use: The ACE Direct Bilirubin Reagent is intended for the quantitative determination of direct bilirubin concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders, including hepatitis and gall bladder block. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only

# Indications for Use

510(k) Number (if known): k123953

Device Name:

ACE Total Bilirubin Reagent

Indications for Use: The ACE Total Bilirubin Reagent is intended for the quantitative determination of total bilirubin concentration in serum and lithium heparin plasma using the ACE, ACE Alera and ACE Axcel Clinical Chemistry System. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders, including hepatitis and gall bladder block. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

# Device Name:

ACE Magnesium Reagent

Indications for Use: The ACE Magnesium Reagent is intended for the quantitative determination of magnesium in serum and lithium heparin plasma using the ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium). This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.